Trabalho aceito no Congresso Europeu de Hematologia – EHA 2021 e para o American Society of Clinical Oncology (ASCO) Annual Meeting 2021, Virtual, June 4–8, 2021

• Abstract Submission 14. Myeloma and other monoclonal gammopathies – Clinical EHA-2172 ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA ACCORDING TO PRIOR LINES OF TREATMENT AND REFRACTORY STATUS: IKEMA SUBGROUP ANALYSIS Meletios-Athanasios Dimopoulos* 1 , Philippe Moreau2 , Bradley Augustson3 , Nelson Castro4 , Tomas Pika5 , Sosana Delimpasi6 , Javier De la Rubia7 , Angelo Maiolino8 , Anthony Reiman9 , Irina Kryuchkova10, Joaquin Martinez-Lopez11 , Thomas Martin12, Joseph Mikhael13, Kwee Yong14, Marie-Laure Risse15, Gaelle Asset16, Sylvia Marion17, Roman Hajek18 1The National and Kapodistrian University of Athens, Athens, Greece, 2Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France, 3Sir Charles Gairdner Hospital, Perth, Australia, 4Hospital de Cancer de Barretos, São Paulo, Brazil, 5Department of Hemato-Oncology, University Hospital Olomouc, Olomouc, Czech Republic, 6Department of Haematology, General Hospital of Athens, Athens, Greece, 7Hematology Department, University Hospital La Fe, Valencia, Spain, 8 Instituto COI de Ensino e Pesquisa, Rio de Janeiro, Brazil, 9Department of Oncology, Saint John Regional Hospital, Dalhousie University and University of New Brunswick, Saint John, Canada, 10Research Institute of Clinical Immunology, Novosibirsk, Russian Federation, 11Departamento de Hematología, Hospital 12 de Octubre, Complutense University, CNIO, Madrid, Spain, 12UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, 13Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, United States, 14 Department of Haematology, University College Hospital, London, United Kingdom, 15Sanofi R&D, Vitry/Alfortville, 16 Sanofi R&D, Chilly-Mazarin, France, 17Sanofi R&D, Cambridge, United States, 18Department of Hemato-Oncology, University Hospital Ostrava and University of Ostrava, Ostrava, Czech Republic
• Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicenter, randomized, open-label, phase 3 study
  John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkciewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, Laura Maria Fogliatto, Iara Gonçalves, Jose SR de Oliveira, Valeria Buccheri, Guilherme F Perini, Neta Goldschmidt, Irina Kriashok, Michael Dickinson, Mieckzyslaw Komarnicki, Andrew McDonald, Muhit Ozcan, Naohiro Sekigushi, Ying Zhu, Akash Nahar, Patricia Marinello, Pier Luigi Zinzani, on behalf of KEYNOTE-204 investigators
  Lancet Oncology March 12, 2021. http://doi.org/101016/S1470-2045(21)00005-X
• Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation

Edvan De Queiroz Crusoe, Fabiana Higashi, Gracia Martinez, Rosane Bittencourt, Jorge Vaz Pinto Neto, Lais Sousa, Rodrigo Santucci, Roberto José Pessoa Magalhães, Gilberto Colli, Renata Ferreira Marques Nunes, Glaciano Ribeiro, Jandir Nicacio, Karla Richter Zanella, Jose Mauro Kutner, Andre Magalhaes, Danielle Leao, Abrahão Elias Hallack Neto, Walter Braga, Emanuella G Souza, Antonio Julio A.M. Guimaraes, Giovanna Steffenello Durigon, Dani Laks, Angelo Maiolino, Vania Tietsche de Moraes Hungria, , on behalf of GBRAM- (GRUPO BRASILEIRO DE MIELOMA)